Exploration of Circulating Tumor Cell (CTC) Conversion and CTC0 As Prognostic Biomarkers for Efficacy in TALAPRO-2: Phase 3 Study of Talazoparib (TALA) + Enzalutamide (ENZA) Vs Placebo (PBO) + ENZA As First-Line (1L) Treatment in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).